Is Lupin technically bullish or bearish?

Recent Technical Trend Shift

As of 28 November 2025, Lupin’s technical trend has upgraded from mildly bullish to bullish, signalling a positive shift in market sentiment. This change is significant as it reflects a consolidation of various technical indicators pointing towards upward momentum. The current price stands at ₹2,081, slightly above the previous close of ₹2,072.40, with intraday highs touching ₹2,091.25 and lows at ₹2,068.75. The stock remains comfortably above its 52-week low of ₹1,774.00, though still below the 52-week high of ₹2,403.45, indicating room for further upside.

Weekly and Monthly Technical Indicators

Examining the Moving Average Convergence Divergence (MACD), the weekly chart shows a bullish signal, suggesting positive momentum in the near term. However, the monthly MACD remains mildly bearish, indicating some caution over the longer horizon. This divergence between weekly and monthly MACD readings is not uncommon in stocks undergoing transitional phases but warrants close monitoring.

The Relative Strength Index (RSI) on both weekly and monthly timeframes currently offers no clear signal, implying that the stock is neither overbought nor oversold. This neutral RSI stance supports the view that Lupin is in a consolidation phase, potentially setting up for a sustained move.

Bollinger Bands provide further clarity, with both weekly and monthly charts showing bullish indications. The price action near the upper band on the weekly scale suggests strong buying interest, while the monthly band alignment supports a longer-term positive outlook.

Moving Averages and Other Momentum Indicators

Daily moving averages reinforce the bullish case, with the stock price trading above key averages, signalling short-term strength. The Know Sure Thing (KST) indicator is bullish on the weekly chart but mildly bearish on the monthly, echoing the mixed signals seen in MACD. Dow Theory assessments on both weekly and monthly timeframes lean mildly bullish, adding to the positive technical narrative.

On-Balance Volume (OBV) readings are mildly bullish weekly and bullish monthly, indicating that volume trends support price advances. This volume-price relationship is crucial as it confirms that buying interest is accompanied by adequate trading activity, a hallmark of sustainable moves.

Price Performance Relative to Sensex

Lupin’s recent price returns have outpaced the Sensex over short-term periods, reinforcing the bullish technical signals. Over the past week, Lupin gained 2.58%, compared to the Sensex’s 0.56%. The one-month return is even more impressive at 8.32%, significantly higher than the Sensex’s 1.27%. These short-term gains align with the weekly bullish technical indicators and suggest strong investor interest.

However, the year-to-date (YTD) return for Lupin is negative at -11.48%, contrasting sharply with the Sensex’s positive 9.68%. This underperformance over the longer term may reflect sector-specific challenges or company-specific issues that have weighed on the stock. Over the one-year horizon, Lupin’s return of 4.05% still lags behind the Sensex’s 8.43%, indicating that while recent momentum is positive, the stock has some ground to recover.

Looking further back, Lupin has delivered robust multi-year returns, with a three-year gain of 183.63% versus the Sensex’s 37.12%, and a five-year return of 133.35% compared to the Sensex’s 94.13%. These figures highlight Lupin’s strong growth trajectory over the medium term, despite recent volatility. The ten-year return of 14.68% trails the Sensex’s 228.02%, reflecting the broader market’s exceptional long-term performance.

Technical Outlook and Investor Implications

The current technical landscape for Lupin is predominantly bullish, especially on weekly and daily timeframes. The upgrade from mildly bullish to bullish trend status underscores growing confidence among traders and investors. Key momentum indicators such as MACD, Bollinger Bands, moving averages, and OBV support this positive stance.

Nevertheless, the mildly bearish monthly MACD and KST indicators suggest that caution is warranted for investors with a longer-term horizon. The absence of strong RSI signals indicates that the stock is not yet overextended, which could mean further upside potential remains before any significant correction.

Price action near the 52-week high of ₹2,403.45 will be a critical level to watch. A sustained breakout above this mark could confirm a new leg higher, while failure to breach resistance may lead to consolidation or retracement. Volume trends, as indicated by OBV, will be an important confirmation tool for any breakout.

Sector Context and Broader Market Considerations

Lupin operates within the Pharmaceuticals & Biotechnology sector, which has experienced mixed fortunes amid regulatory scrutiny, pricing pressures, and evolving global demand. The sector’s performance often influences Lupin’s stock trajectory, making it essential to consider broader industry trends alongside technical signals.

Given the sector’s inherent volatility, Lupin’s technical bullishness is a positive sign that the company may be poised to capitalise on favourable developments such as new drug approvals, expansion into emerging markets, or operational efficiencies. Investors should monitor sector news and macroeconomic factors that could impact sentiment.

In summary, Lupin’s technical indicators suggest a bullish momentum gaining traction, particularly in the short to medium term. While some monthly signals advise prudence, the overall trend supports a constructive outlook for the stock, especially if it can sustain gains above key resistance levels.

Conclusion

To answer the question directly: Lupin is currently exhibiting a technically bullish profile. The recent upgrade in trend status, combined with strong weekly and daily momentum indicators, points to positive price action ahead. However, investors should remain mindful of mixed monthly signals and the stock’s recent underperformance relative to the Sensex on a year-to-date basis.

For traders and investors, Lupin presents an opportunity to participate in a pharmaceutical leader showing renewed technical strength. Close attention to price levels, volume confirmation, and sector developments will be key to navigating the stock’s next moves effectively.

Limited Time Only! Subscribe for Rs. 12,999 and get 1 Year of MojoOne + an Additional Year Completely FREE. Don't miss out on this exclusive offer. Claim Your Free Year →